Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives

References

• ShuaiKHalpernJten HoeveJRaoXSawyersCLConstitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemiaOncogene19961322472548710363
   PubMed Web of Science ®Google Scholar
• RaitanoABHalpernJRHambuchTMSawyersCLThe BCR-ABL leukemia oncogene activates Jun kinase and requires Jun for transformationProc Natl Acad Sci USA1995922511746117508524841
   PubMed Web of Science ®Google Scholar
• OttmannOGPfeiferHManagement of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)Hematol Am Soc Hematol Educ Prog2009371381
   Web of Science ®Google Scholar
• GotzGWehHJWalterTAClinical and prognostic significance of the Philadelphia chromosome in adult patients with acute lymphoblastic leukemiaAnn Hematol1992642971001554802
   PubMed Web of Science ®Google Scholar
• GleissnerBGokbugetNBartramCRLeading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysisBlood20029951536154311861265
   PubMed Web of Science ®Google Scholar
• SiveJIBuckGFieldingAOutcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trialBr J Haematol2012157446347122409379
   PubMed Web of Science ®Google Scholar
• HochhausALarsonRAGuilhotFLong-term outcomes of imatinib treatment for chronic myeloid leukemiaN Engl J Med20173761091792728273028
   PubMed Web of Science ®Google Scholar
• ErnstTLa RoseePMullerMCHochhausABCR-ABL mutations in chronic myeloid leukemiaHematolOncolClinNAm20112559971008vvi
   Google Scholar
• JabbourEKantarjianHMSaglioGEarly response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)Blood2014123449450024311723
   PubMed Web of Science ®Google Scholar
• LarsonRAHochhausAHughesTPNilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year followupLeukemia201226102197220322699418
   PubMed Web of Science ®Google Scholar
• LeeSKimYJMinCKThe effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemiaBlood200510593449345715657178
   PubMed Web of Science ®Google Scholar
• MizutaSMatsuoKNishiwakiSPretransplant administration of imatinib for allo-HSCT in patients with BCR-ABL-positive acute lymphoblastic leukemiaBlood2014123152325233224591204
   PubMed Web of Science ®Google Scholar
• LuLSaundersVALeclercqTMHughesTPWhiteDLPonatinib is not transported by ABCB1, ABCG2 or OCT-1 in CML cellsLeukemia20152981792179425676419
   PubMed Web of Science ®Google Scholar
• O’HareTShakespeareWCZhuXAP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistanceCancer Cell200916540141219878872
   PubMed Web of Science ®Google Scholar
• CortesJEKantarjianHShahNPPonatinib in refractory Philadelphia chromosome-positive leukemiasN Engl J Med2012367222075208823190221
   PubMed Web of Science ®Google Scholar
• CortesJEKimDWPinilla-IbarzJA phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemiasN Engl J Med2013369191783179624180494
   PubMed Web of Science ®Google Scholar
• CortesJPonatinib efficacy and safety in heavily pretreated leukemia patients: 3 year results of the PACE trialHaematologica2015100Suppl164
   Google Scholar
• NicoliniFEIbrahimARSoveriniSThe BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysisHaematologica201398101510151623716543
   PubMed Web of Science ®Google Scholar
• MillerGDBrunoBJLimCSResistant mutations in CML and Ph(+) ALL - role of ponatinibBiologics2014824325425349473
   PubMedGoogle Scholar
• DeiningerMWHodgsonJGShahNPCompound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patientsBlood2016127670371226603839
   PubMed Web of Science ®Google Scholar
• LiptonJHBrydenPSidhuMKComparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitorsLeuk Res2015391586425466286
   PubMed Web of Science ®Google Scholar
• LiptonJHChuahCGuerci-BreslerAPonatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trialLancet Oncol201617561262127083332
   PubMed Web of Science ®Google Scholar
• JainPKantarjianHJabbourEPonatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 studyLancet Haematol201529e376e38326436130
   PubMed Web of Science ®Google Scholar
• TojoAKyoTYamamotoKPonatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1/2 studyInt J Hematol2017106338539728444644
   PubMed Web of Science ®Google Scholar
• JabbourEKantarjianHO’BrienSThe achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitorsBlood20111181745414546 quiz 475921803854
   PubMed Web of Science ®Google Scholar
• JabbourEKantarjianHRavandiFCombination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 studyLancet Oncol201516151547155526432046
   PubMed Web of Science ®Google Scholar
• MaitiAKantarjianHHyper-CVAD plus ponatinib as frontline therapy in Philadelphia chromosome-positive acute lymphoblastic leukemia: updated results of a phase II trialClin Lymphoma Myeloma Leuk201717S257S258
   Web of Science ®Google Scholar
• SasakiKJabbourEJRavandiFHyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a propensity score analysisCancer2016122233650365627479888
   PubMed Web of Science ®Google Scholar
• GainorJFChabnerBAPonatinib: accelerated disapprovalOncologist201520884784826173838
   PubMed Web of Science ®Google Scholar
• HaguetHDouxfilsJMullierFChatelainCGrauxCDogneJMRisk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysisExpert Opin Drug Saf201716151227852118
   PubMed Web of Science ®Google Scholar
• CortesJETalpazMKantarjianHPonatinib in Philadelphia chromosome-positive leukemiasN Engl J Med20143706577
   Web of Science ®Google Scholar
• DorerDJKnickerbockerRKBaccaraniMImpact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patientsLeuk Res201648849127505637
   PubMed Web of Science ®Google Scholar
• RiveraVMPritchardJRGonzalvezFComparative TKI profiling analyses to explore potential mechanisms of ponatinib-associated arterial adverse eventsBlood20141241784A
   Web of Science ®Google Scholar
• ValentPHadzijusufovicESchernthanerGHWolfDReaDle CoutrePVascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitorsBlood2015125690190625525119
   PubMed Web of Science ®Google Scholar
• HadzijusufovicEKirchmairRTheurlMPonatinib exerts multiple effects on vascular endothelial cells: possible mechanisms and explanations for the adverse vascular events seen in CML patients treated with ponatinibBlood20161281883
   Web of Science ®Google Scholar
• ValentPBaghestanianMBanklHCNew aspects in thrombosis research: possible role of mast cells as profibrinolytic and antithrombotic cellsThromb Haemost200287578679012038777
   PubMed Web of Science ®Google Scholar
• NeelakantanPMarinDLaffanMGoldmanJApperleyJMilojkovicDPlatelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor therapyHaematologica2012979144422532521
   PubMed Web of Science ®Google Scholar
• NazhaARomoCGKantarjianHCortesJThe clinical impact of ponatinib on the risk of bleeding in patients with chronic myeloid leukemiaHaematologica20139810e13124091930
   PubMed Web of Science ®Google Scholar
• PochMartell MSibaiHDeotareULiptonJHPonatinib in the therapy of chronic myeloid leukemiaExpert Rev Hematol201691092393227590270
   PubMed Web of Science ®Google Scholar
• MassaroFMolicaMBrecciaMPonatinib: a review of efficacy and safetyCurr Cancer Drug Targets Epub2017102
   Web of Science ®Google Scholar
• BrecciaMPregnoPSpallarossaPIdentification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinionAnn Hematol201796454955827686083
   PubMed Web of Science ®Google Scholar
• MoslehiJJDeiningerMTyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemiaJ Clin Oncol201533354210421826371140
   PubMed Web of Science ®Google Scholar
• MontazeriKUnittCFoodyJMHarrisJRPartridgeAHMoslehiJABCDE steps to prevent heart disease in breast cancer survivorsCirculation201413018e157e15925462826
   PubMed Web of Science ®Google Scholar
• HsuSTonVKDominique AshenMA clinician’s guide to the ABCs of cardiovascular disease prevention: the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease and American College of Cardiology Cardiosource Approach to the Million Hearts InitiativeClin Cardiol201336738339323670948
   PubMed Web of Science ®Google Scholar
• BaccaraniMDeiningerMWRostiGEuropean Leukemia Net recommendations for the management of chronic myeloid leukemia: 2013Blood2013122687288423803709
   PubMed Web of Science ®Google Scholar
• RavandiFKebriaeiPPhiladelphia chromosome-positive acute lymphoblastic leukemiaHematol Oncol Clin North Am200923510431063vi19825452
   PubMed Web of Science ®Google Scholar
• HirschbuehlKRankAPfeifferTPonatinib given for advanced leukemia relapse after allo-SCTBone Marrow Transplant201550459960025581405
   PubMed Web of Science ®Google Scholar
• PetrungaroAGentileMMazzoneCPonatinib-induced graft-versus-host disease/graft-versus-leukemia effect in a patient with Philadelphia-positive acute lymphoblastic leukemia without the T315I mutation relapsing after allogeneic transplantChemotherapy201762635335628810255
   PubMed Web of Science ®Google Scholar
• RenziDMarchesiFDe AngelisGPonatinib induces a persistent molecular response and graft-versus-host disease/graft-versus-leukemia effect in a patient with Philadelphia-positive acute lymphoblastic leukemia with a T315I mutation following early relapse after allogeneic transplantChemotherapy2017621586127618144
   PubMed Web of Science ®Google Scholar
• NicoliniFEBasakGWKimDWOverall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutationCancer2017123152875288028387926
   PubMed Web of Science ®Google Scholar
• ParkerWTYeungDTYeomanALThe impact of multiple low-level BCR-ABL1 mutations on response to ponatinibBlood2016127151870188026773037
   PubMed Web of Science ®Google Scholar
• BaerCKernWKochSUltra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemiaHaematologica2016101783083827102501
   PubMed Web of Science ®Google Scholar
• MahonFXReaDGuilhotJDiscontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trialLancet Oncol201011111029103520965785
   PubMed Web of Science ®Google Scholar
• ValentPHerndlhoferSSchneeweissMTKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CMLOncotarget2017814230612307228416739
   PubMedGoogle Scholar
• FoaRVitaleAVignettiMDasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemiaBlood2011118256521652821931113
   PubMed Web of Science ®Google Scholar
• MalagolaMPapayannidisCBaccaraniMTyrosine kinase inhibitors in Ph+ acute lymphoblastic leukaemia: facts and perspectivesAnn Hematol201695568169326891878
   PubMed Web of Science ®Google Scholar
• CarpenterPASnyderDSFlowersMEProphylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemiaBlood200710972791279317119111
   PubMed Web of Science ®Google Scholar
• WassmannBPfeiferHStadlerMEarly molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)Blood2005106245846315817679
   PubMed Web of Science ®Google Scholar
• ShortNJKantarjianHJabbourERavandiFWhich tyrosine kinase inhibitor should we use to treat Philadelphia chromosome-positive acute lymphoblastic leukemia?Best Pract Res Clin Haematol201730319320029050692
   PubMed Web of Science ®Google Scholar